Dose determination study of Nanoparticulated Brown Rice Germ Extract on Body Fat Reduction by Daily Ingestion.

Dose determination study of Nanoparticulated Brown Rice Germ Extract on Body Fat Reduction by Daily Ingestion. - Effects of Reducing Body Fat by Daily Ingestion of Nanoparticulated Brown Rice Germ Extract.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000029511

Enrollment

120

Registered

2017-10-13

Start date

2017-10-18

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy adults

Interventions

Ingestion of 2 tablets of nanoparticulated brown rice germ extract (high dose) daily for 12 weeks. Ingestion of 2 tablets of nanoparticulated brown rice germ extract (medium dose) daily for 12 weeks.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.Subjects whose BMI is >=23 kg/m2 and <30 kg/m2. 2.Subjects whose Abdominal visceral fat area is <100cm2. 3.Subjects who agree to participate in this study with a written informed consent.

Exclusion criteria

Exclusion criteria: 1.Subjects who are under physician's advice, treatment and/or medication for obese, hyperlipidemia and diabetes. 2.Subjects with familial hypercholesterolemia. 3.Subjects with serious cerebrovascular, cardiac, hepatic, renal, gastrointestinal diseases, and/or affected with infectious diseases requiring reports to the authorities. 4.Pacemaker or defibrillator users. 5.Subjects with major surgical history relevant to digestive system such as gastrectomy, gastrorrhaphy, enterectomy, etc. 6.Subjects with unusually high and/or low blood pressure and/or abnormal hematological data. 7.Subjects with severe anemia. 8.Pre- or post-menopausal women complaining obvious physical changes. 9.Subjects who are at risk of having allergic reactions to drugs or foods, especially gramineae. 10.Subjects who regularly take medicine, functional foods, and/or supplements which would affect BW and BFP. 11.Subjects who regularly take medicine, functional foods, and/or supplements which would affect blood lipid levels. 12.Subjects who regularly take medicine, functional foods and/or supplements which would affect glucose metabolism. 13.Heavy smokers, alcohol addicts or subjects with the eating disordered lifestyle. 14.Subjects who donated either 400ml whole blood within 16 weeks (women) /12 weeks (men) or 200ml whole blood within 4 weeks or blood components within 2 weeks prior to the current study. 15.Pregnant or lactating women or women expect to be pregnant during this study. 16.Subjects who currently participate in other clinical trials or participated within the last 4 weeks prior to the current study. 17.Any other medical and/ or health reasons unfavorable to participation into the current study judged by the principal investigator.

Design outcomes

Primary

Measure	Time frame
Abdominal visceral fat area after 4, 8 and 12 weeks of ingestion.	—

Secondary

Measure	Time frame
body weight, BFP, BMI, waist circumference, TC, LDL-C, HDL-C, TG, LDL-C/HDL-C, non-HDL, fasting blood glucose levels, HbA1c, insulin, HOMA-IR, adiponectin , leptin, Olfactory test and DASC-21.	—

Countries

Japan

Contacts

Public ContactDir. Prof. Jun NISHIHIRA, M.D., Ph.D.

Hokkaido Information University Health Information Science Center

nishihira@do-johodai.ac.jp011-385-4430

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026